In patients with AF and COVID-19 who receive DOAC, 30-day mortality risk is similar for nirmatrelvir/ritonavir and RdRp ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results